Synced daily from ClinicalTrials.gov via AACT. Last sync: .
13 Repotrectinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 11 indications (including Healthy Volunteers & Metastatic Solid Tumor) and 1,010 total planned enrollment. 1 Phase 3 Repotrectinib trial and 3 Phase 2 are listed. 6 Repotrectinib clinical trials are actively recruiting at 23 U.S. sites across 14 states. Most recent activity: NCT06552234 (Sep 2031).
Where to Participate: All Repotrectinib Trial Sites in the U.S. (23 sites across 14 states)
Every actively recruiting Repotrectinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
NCT05828277withdrawnA Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
NCT06408168terminatedPhase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
All Repotrectinib trials (13)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
13 Repotrectinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants. 3 are marked completed.
Are Repotrectinib clinical trials recruiting in 2026?
Yes — 6 Repotrectinib trials are actively recruiting in 2026, with 23 U.S. sites across 14 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Repotrectinib being studied for?
Repotrectinib is being studied for Healthy Volunteers, Metastatic Solid Tumor, Metastatic Solid Tumors, Locally Advanced Solid Tumors, Hormone Receptor-positive Human Epidermal Growth Factor 2-negative and 13 more. The trials are grouped by indication on this page.
What phase is Repotrectinib in?
Repotrectinib clinical trials span 1 Phase 3, 3 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Repotrectinib clinical trials?
The lead sponsor across the most Repotrectinib trials is Bristol-Myers Squibb, with 6 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Repotrectinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.